Morgan Stanley reiterates Lockheed Martin stock rating on missile production deal

Lockheed announced a framework to accelerate Precision Strike Missile production ~4x; Morgan Stanley reiterated an Equalweight rating and $675 price target vs LMT trading at $621.73 (up 27% over six months). The company also secured roughly $761M in additional Department of War contracts (largest $700.4M), a NOK2bn F-35 component agreement with Kongsberg, and delivered a UH-60MX with MATRIX autonomy—while Honeywell signed a separate $500M DoW supplier framework. Morgan Stanley cites structurally higher DoW demand, improved out-year funding visibility and potential margin expansion from higher production rates, with the Iran conflict adding urgency to replenishment and capacity expansion.

Analysis

A sustained policy-driven push to accelerate munitions and missile output paradoxically creates a two-phase P&L story: an initial squeeze on margins as primes and suppliers pay premiums for overtime, expedited freight, and scarce specialty inputs, followed by multi-year margin tailwinds as fixed costs are absorbed and learning curves compress unit costs. Expect working capital to rise meaningfully in the first 6–18 months as inventory and WIP build to meet cadence targets; free cash flow improvement should lag reported revenue by ~6–12 months.

Competitive benefits will be highly idiosyncratic. Firms owning critical long-lead inputs or with vertically integrated manufacturing can convert capacity expansion into durable share gains and pricing power, while pure assemblers that rely on third‑party castings/electronics will struggle with pass-throughs and schedule risk. Small subcontractors with limited balance sheets are the likely choke points — their need to invest in tooling creates both an opportunity (pricing power) and a fragility (execution risk and revenue concentration).

Catalysts and reversal vectors are concentrated on two timelines: near-term (days–months) headlines around award scope, supplier failures, or appropriation language that reprice risk; and medium-term (6–24 months) operational readouts — supplier throughput, cycle-times, and margin reconciliation. The biggest contrarian risk is that market consensus focuses on headline production multipliers and underestimates the cash and lead-time drag embedded in a rapid ramp, leaving multiples vulnerable if margin expansion is delayed.

Given these mechanics, capital should favor balance-sheet-light suppliers with proven surge experience and primes with optionality in aftermarket/upgrade revenue. Defensive hedges against a de‑escalation or procurement pause (short-dated protection) materially reduce tail downside during the execution window.

Key Decisions for Investors

• LMT — tactical 12-month call spread: buy a modestly OTM 12-month call (≈5% OTM) and fund by selling a higher strike (~25% OTM) to express asymmetric upside to a successful ramp while capping premium outlay. Target 15–25% net upside; max loss = paid premium. Use position size = 1–2% NAV.
• HEICO (HEI) — 12–18 month long: buy shares of a specialist parts supplier with low fixed-cost base and demonstrated surge execution. Target +30–50% if awarded incremental supply slots; set stop-loss at -15% to protect against award loss or inventory hangover.
• L3Harris (LHX) / LMT pair — 12–24 month pair trade: long LHX and short LMT (size equal $ exposure) to capture relative re-rating if subcontractors and mid‑tier integrators win allocation and pricing power. Pair target +20% net; unwind if relative gap widens >12% adverse.
• If long equities across the group — sell short-dated (30–90 day) covered calls to monetize implied volatility ahead of mid-year production and budget data releases. This lowers breakeven and hedges headline-driven pullbacks while preserving upside through longer dated calls.